Respiratory Syncytial Virus News and Research

RSS

Oxford Nanopore Technologies partners with UK Government to roll out LamPORE, a new generation of COVID-19 test

Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test.

From Oxford Nanopore Technologies 3 Aug 2020

Maternal vaccination could protect infants against RSV illness

Immunizing pregnant women with a potential vaccine against RSV could prevent the most common cause of pneumonia in their babies.

3 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

Children carry 100 times more SARS-CoV-2 virus as adults, study says

As the coronavirus disease (COVID-19) continues to wreak havoc across the globe, it has been thought that children mostly seemed to be spared by severe illness. In the majority of cases, children infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only develop a mild illness, with some tagged as asymptomatic.

31 Jul 2020

Researchers report a liquid biopsy for COVID-19

A new study published on the preprint server medRxiv in July 2020 reports the potential of cell-free DNA as a marker of the severity of disease in COVID-19. This could help triage patients as well as provide a prognostic marker.

30 Jul 2020

As winter comes other viruses will compete with SARS-CoV-2 for susceptible hosts

A new study published on the preprint server medRxiv in July 2020 traces how COVID-19 became the predominant cause of respiratory infection in the period from early January until the present.

10 Jul 2020

Remdesivir potently inhibits SARS-CoV-2 in human lung cell cultures

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better.

9 Jul 2020

Ozone gas can provide a safe means to disinfect personal protective equipment

A new study shows that ozone gas, a highly reactive chemical composed of three oxygen atoms, could provide a safe means for disinfecting certain types of personal protective equipment that are in high demand for shielding health care personnel from Covid-19.

9 Jul 2020

UConn researchers tackle a vexing problem in the development of vaccines

Researchers at UConn's Center of Excellence in Vaccine Research have made a breakthrough in vaccine development for a common and difficult to treat pneumonia-causing pathogen. Their research was recently published in the Nature Partner Journal - Vaccines.

17 Jun 2020

Scientists isolate powerful SARS-CoV-2 -neutralizing antibodies from COVID-19 patients

A new study has shown that potent antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help protect against COVID-19 infection. Preliminary results in animal studies have so far proven successful. The study titled, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model," was published in the latest issue of the journal Science.

17 Jun 2020

Antidepressant fluoxetine (Prozac) suppresses replication of SARS-CoV-2

A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.

16 Jun 2020

Human antibodies provide powerful protection against SARS-CoV-2 in animal tests

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures.

15 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Study sheds new light on how respiratory virus breaks into cells to cause infection

New research from University of Alberta microbiologists has shed new light on how the respiratory syncytial virus (RSV)--one of the most common viral infections--breaks into our cells to cause infection.

3 Jun 2020

Prediction of incubation period for COVID-19 and other viruses

A new study published on the preprint server bioRxiv* in May 2020 provides a method to estimate the incubation period for any new pathogen, which could help to define the optimal quarantine period necessary to keep the spread of the causative agent in check.

22 May 2020

Certain corticosteroid could improve severe COVID-19, say researchers

Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).

20 May 2020

Local variations in climate not likely to drive early COVID-19 pandemic

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal Science.

18 May 2020

Sanford director receives major grant to advance broad-spectrum antivirals for respiratory diseases

Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that Sumit Chanda, Ph.D., has received a $10.2 million, four-year grant from the Department of Defense to develop and advance broad-spectrum antivirals for respiratory diseases.

12 May 2020

Perspective: Finding the fastest pathway to COVID-19 vaccine development

When seeking the fastest pathway to a vaccine to prevent coronavirus disease 19 (COVID-19), defining the stakes and potential hurdles is critical, says Barney Graham in this Perspective.

9 May 2020

New approach for easier detection of SARS-CoV-2 via swabs and saliva

A recent Israeli study points toward Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) as a potentially effective tool for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on-the-spot detection by using swabs or saliva – addressing the community need for simple surveillance.

28 Apr 2020